286459-94-7

Upstream product

• 7790-94-5 chlorosulfonic acid 
• 13610-09-8 but-2-ynyloxybenzene 
• 825-90-1 sodium p-hydroxybenzenesulfonate 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 287403-35-4 2-(4-but-2-ynyloxy-benzenesulfonylamino)-N-hydroxy-2-methyl-propionic acid 
• 287096-71-3 tert-butyl 3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)propanoate 
• 608518-52-1 (R)-2-(4-But-2-ynyloxy-benzenesulfonylamino)-propionic acid 
• 287406-84-2 2-[(4-but-2-ynyloxy-benzenesulfonyl)-methyl-amino]-propionic acid 
• 287406-81-9 (R)-2-(4-But-2-ynyloxy-benzenesulfonylamino)-3,3-dimethyl-butyric acid 
• 608518-54-3 (2R,3S)-2-(4-But-2-ynyloxy-benzenesulfonylamino)-3-hydroxy-butyric acid 
• 608518-53-2 (R)-2-(4-But-2-ynyloxy-benzenesulfonylamino)-3-methyl-butyric acid 
• 287403-09-2 2-[(4-but-2-ynyloxy-benzenesulfonyl)-methyl-amino]-3-methyl-butyric acid 
• 287201-95-0 4-but-2-ynyloxy-benzenethiol 
• 287408-83-7 2-({[4-(2-butynyloxy)-phenyl]sulfonyl}amino)-4-[(2-hydroxyethyl)sulfanyl]butanoic acid 
• 937802-37-4 C₁₅H₁₉NO₄S 
• 718638-37-0 4-but-2-ynyloxy-N-[(R)-3-hydroxypyrrolidinyl]benzenesulfonamide 
• 937802-35-2 C₁₃H₁₅NO₄S 
• 937802-36-3 C₁₄H₁₇NO₄S 

Relevant academic research and scientific papers

Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis

Targeting the TNFα pathway is a validated approach to the treatment of psoriasis. In this pathway, TACE stands out as a druggable target and has been the focus of in-house research programs. In this article, we present the discovery of clinical candidate

NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS

Provided herein are novel benzenesulfonamide compounds having a structure of formula (I) below: as well as to the method for synthesizing same and to the use thereof in pharmaceutical compositions to be used in human or veterinary medicine, as well as to

NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS

Benzenesulfonamide compounds having a structure of formula (I) are described. Also described, are methods for synthesizing the compounds and to the use thereof in pharmaceutical compositions for human or veterinary medicine and in cosmetic compositions.

ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS

Compounds of the formula:useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.

ACETYLENIC SULFONAMIDE THIOL TACE INHIBITORS

Compounds of formula (B): (1a), or (1b), (1c) are provided wherein the variables are as defined herein which are useful in disease conditions mediated by TNF- alpha , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple

HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS

Compounds of formula (I) are useful in treating disease conditions mediated by TNF- alpha such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS

Compound of the formula (B) are useful in treating disease conditions mediated by TNF- alpha , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS

Hydroxamic acids having formula (B) wherein the variables are as defined herein, are useful in treating disease conditions mediated by TNF- alpha such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's d

2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS

Compounds having formula (1) are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.

2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids

Compounds having the following formula: ? are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.